Use access key #2 to skip to page content.
$3.32 0.13 (4.08%)
12/4/2008 11:10 AM

Orthovita, Inc. (VITA)

CAPS Rating:
****

A spine and orthopedic biosurgery company which develops and markets synthetic-based biomaterial products for use in spine surgery, the repair of fractures and a range of clinical needs in the trauma, joint reconstruction, revision and extremities markets

View All Commentary (VITA)

Recs

1

Avatar flexnexus (60.94) Submitted: 8/22/07 8:43 PM : Outperform Start Price: $2.83 VITA Score: 56.64

Dilution rounds look like they are finally over. Major investors have stepped up and bought more. Sales traction is already at about $60M annually with 30% growth. Cortoss is in the cusp of marketing approval in early to mid 2008. Sales of this product should increase revenue growth to over 50% annually. Marketcap is only about $200M right now.

Orthovita was also able to secure debt financing from one of it's equity investors. I believe institutions are going to start accumulating now that dilution looks like it's done with.

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners

Sponsored Links